IDV vehicle
36E79724D0004
NEW AWARD FOR TERIFLUNOMIDE TABLETS WITH AVKARE LLC. PERIOD OF PERFORMANCE IS DEC 23, 2023 TO DEC 22, 2024 WITH FOUR ONE-YEAR OPTIONS.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Veterans Affairs |
| Office | NAC PHARMACEUTICALS (36E797) |
| NAICS | 325412 — Pharmaceutical Preparation Manufacturing |
| PSC | 6505 — Drugs and Biologicals |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $0 |
| Current contract value | Not reported |
| Potential contract value / ceiling | $995.7K |
| Start date | Dec 23, 2023 |
| Current end date | Not available |
| Potential end date | Not available |
| Latest award activity | Aug 31, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 8 of 8 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 31, 2026 | P00007 | $0 | THIS MODIFICATION IS ISSUED TO INCORPORATE EO 14398 DEI DISCRIMINATION INTO NATIONAL CONTRACT 36E79724D0004. |
| Dec 11, 2025 | P00006 | $0 | THIS MODIFICATION IS ISSUED TO INCORPORATE AVKARE, LLC 2026 SUBCONTRACTING PLAN INTO NATIONAL CONTRACT 36E79724D0004. |
| Oct 28, 2025 | P00005 | $0 | THIS MODIFICATION IS ISSUED TO EXERCISE THE 2ND OPTION YEAR FOR TERIFLUNOMIDE TABLETS UNDER NATIONAL CONTRACT 36E79724D0004. |
| Dec 27, 2024 | P00004 | $0 | THIS MODIFICATION IS ISSUED TO INCORPORATE AVKARE, LLC 2025 SUBCONTRACTING PLAN INTO CONTRACT 36E79724D0004. |
| Nov 14, 2024 | P00003 | $0 | THIS MODIFICATION IS ISSUED TO EXERCISE THE 1ST OPTION YEAR FOR TERIFLUNOMIDE TABLETS UNDER CONTRACT 36E79724D0004 WITH AVKARE LLC. |
| Feb 20, 2024 | P00002 | $0 | THIS MODIFICATION IS ISSUED TO UPDATE THE TERMS OF THE CRF PAYMENT REMITTAL AND SUBMISSION OF QUARTERLY SALES REPORTS. |
| Dec 6, 2023 | P00001 | $0 | THIS MODIFICATION IS ISSUED TO INCORPORATE AVKARE, LLC 2024 SUBCONTRACTING PLAN FOR THE PERIOD OF JANUARY 1, 2024 -- DECEMBER 31, 2024. |
| Oct 24, 2023 | 0 | $0 | NEW AWARD FOR TERIFLUNOMIDE TABLETS WITH AVKARE LLC. PERIOD OF PERFORMANCE IS DEC 23, 2023 TO DEC 22, 2024 WITH FOUR ONE-YEAR OPTIONS. |
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.